Podcasts about flot

Learning and applying God's 10 problem-solving devices will fortify the FLOT line in your soul (FLOT is an acronym for Forward Line of Troops), preventing outside sources of adversity from becoming internal pressure and stress in your soul. This episode (Part 6) covers the tenth and final device: 10. Occupation with Christ (consistent, sustaining focus on the Lord Jesus Christ). When your soul is saturated with God's Word, you will replicate the thinking of Christ, making every moment in life an opportunity to glorify Him with your faith, trust, obedience, and an incredible love for your Savior.Download Transcript⁠: https://rhem.pub/problem-solving-b037aa

Learning and applying God's 10 problem-solving devices will fortify the FLOT line in your soul (FLOT is an acronym for Forward Line of Troops), preventing outside sources of adversity from becoming internal pressure and stress in your soul. This episode (Part 5) covers the ninth device: 9. Sharing the Happiness of God (the joy resident in the soul's mentality). When you have absolute confidence in God's plan and will for your life, it supercharges your contentment, enabling you to experience His joy in any circumstance.⁠Download Transcript⁠: https://rhem.pub/problem-solving-97bad3

Retrouvez Jacques Lemaître avec toujours plus de musique. Animation : Jacques Lemaître Mise en ondes : Jean-Sébastien Laliberté

Learning and applying God's 10 problem-solving devices will fortify the FLOT line in your soul (FLOT is an acronym for Forward Line of Troops), preventing the outside sources of adversity from becoming the inside pressure of stress in your soul. This episode (Part 4) covers the seventh and eighth devices: 7. Personal Love for God (the motivational virtue) and 8. Impersonal Love for all Mankind (the functional virtue). Your ability to love as God designed and outlined in Scripture adds powerful tools to your problem-solving toolbox.Download Transcript⁠: https://rhem.pub/problem-solving-cc03d3

Vi taler om den svære spirende kærlighed, hvordan vi dater med og uden dating apps og gode date-spots. Det er forår, og for nogle af os betyder det, at det er tid til pollenallergi og let mani. Tid til boglæsning på bænke og koncerter, tilløb til festivaler og summende sommerfugle i maven efter et langt vinterhi. I denne forårsspecial-udgave af Poptillægget giver vi dig – i to afsnit – en badebro ind i foråret. Og vi lover at overshare i panelet - og dele de lytterkommentarer, anbefalinger og spørgsmål, vi har fået i indbakken. Dette er andet afsnit af vores forårsfølelser-special. Producer: Sille Westphal Panel og anbefalinger: Jesper Binzer, forsanger i D-A-D og forfatter til ’Flot kronhjort’, anbefaler kvindelig black metal som ’Witch Club Satan’, ’Konvent’ og ’Vulvatorious’ Johanne Bille, forfatter og journalist, anbefaler ’kvinderne i fængslet’ Mads Axelsen, radiovært og PR- og kommunikationsanvarlig på Blagaard Teater, anbefaler at høre Liss og mindes Søren Holm Vært Lucia Odoom anbefaler Bad Bunny’s tiny desk koncertSee omnystudio.com/listener for privacy information.

Listen as we discuss the highly-awaited ESOPEC trial, which examines treatment regimens for esophageal and EGJ adenocarcinoma. Wildly impress your thoracic attendings or peers with your nuanced knowledge! FLOT who? You'll know. Pull out the paper and listen along! Learning Objectives: -Discuss the patient population in the ESOPEC trial -Discuss the main differences between the ESOPEC trial and the CROSS trial -Describe the main drawbacks between FLOT and the CROSS regimen. Hosts: Chloe Hanson MD, Brian Louie MD, and Peter White MD   Referenced Material https://www.nejm.org/doi/full/10.1056/NEJMoa2409408 Hoeppner J, Brunner T, Schmoor C, Bronsert P, Kulemann B, Claus R, Utzolino S, Izbicki JR, Gockel I, Gerdes B, Ghadimi M, Reichert B, Lock JF, Bruns C, Reitsamer E, Schmeding M, Benedix F, Keck T, Folprecht G, Thuss-Patience P, Neumann UP, Pascher A, Imhof D, Daum S, Strieder T, Krautz C, Zimmermann S, Werner J, Mahlberg R, Illerhaus G, Grimminger P, Lordick F. Perioperative Chemotherapy or Preoperative Chemoradiotherapy in Esophageal Cancer. N Engl J Med. 2025 Jan 23;392(4):323-335. doi: 10.1056/NEJMoa2409408. PMID: 39842010. https://www.nejm.org/doi/full/10.1056/NEJMoa1112088 van Hagen P, Hulshof MC, van Lanschot JJ, Steyerberg EW, van Berge Henegouwen MI, Wijnhoven BP, Richel DJ, Nieuwenhuijzen GA, Hospers GA, Bonenkamp JJ, Cuesta MA, Blaisse RJ, Busch OR, ten Kate FJ, Creemers GJ, Punt CJ, Plukker JT, Verheul HM, Spillenaar Bilgen EJ, van Dekken H, van der Sangen MJ, Rozema T, Biermann K, Beukema JC, Piet AH, van Rij CM, Reinders JG, Tilanus HW, van der Gaast A; CROSS Group. Preoperative chemoradiotherapy for esophageal or junctional cancer. N Engl J Med. 2012 May 31;366(22):2074-84. doi: 10.1056/NEJMoa1112088. PMID: 22646630. https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(18)32557-1/abstract Al-Batran SE, Homann N, Pauligk C, Goetze TO, Meiler J, Kasper S, Kopp HG, Mayer F, Haag GM, Luley K, Lindig U, Schmiegel W, Pohl M, Stoehlmacher J, Folprecht G, Probst S, Prasnikar N, Fischbach W, Mahlberg R, Trojan J, Koenigsmann M, Martens UM, Thuss-Patience P, Egger M, Block A, Heinemann V, Illerhaus G, Moehler M, Schenk M, Kullmann F, Behringer DM, Heike M, Pink D, Teschendorf C, Löhr C, Bernhard H, Schuch G, Rethwisch V, von Weikersthal LF, Hartmann JT, Kneba M, Daum S, Schulmann K, Weniger J, Belle S, Gaiser T, Oduncu FS, Güntner M, Hozaeel W, Reichart A, Jäger E, Kraus T, Mönig S, Bechstein WO, Schuler M, Schmalenberg H, Hofheinz RD; FLOT4-AIO Investigators. Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trial. Lancet. 2019 May 11;393(10184):1948-1957. doi: 10.1016/S0140-6736(18)32557-1. Epub 2019 Apr 11. PMID: 30982686. ***Fellowship Application Link: https://forms.gle/PQgAvGjHrYUqAqTJ9 Please visit https://behindtheknife.org to access other high-yield surgical education podcasts, videos and more. If you liked this episode, check out our recent episodes here: https://app.behindtheknife.org/listen

Learning and applying God's 10 problem-solving devices will fortify the FLOT line in your soul (FLOT is an acronym for Forward Line of Troops), preventing the outside sources of adversity from becoming the inside pressure of stress in your soul. This episode (Part 3) covers the sixth device: 6. Personal Sense of Destiny (the ability to identify God's plan specifically for you). You glorify God when you use God's spiritual assets to solve all your daily problems.⁠Download Transcript⁠: https://rhem.pub/problem-solving-12e72c

durée : 00:03:24 - Capture d'écrans - par : Eva Roque - Une nouvelle série animée pour les 3-5 ans, "Les Moodz", permet aux enfants de mieux comprendre et gérer leurs émotions. Un programme très réussi à voir sur la plateforme gratuite Okoo et France.tv

Det er forår, og for nogle af os betyder det, at det er tid til pollenallergi og let mani. Tid til boglæsning på bænke og koncerter, tilløb til festivaler og summende sommerfugle i maven efter et langt vinterhi. I denne forårsspecial-udgave af Poptillægget giver vi dig – i to afsnit – en badebro ind i foråret. Og vi lover at overshare i panelet - og dele de lytterkommentarer, anbefalinger og spørgsmål, vi har fået i indbakken. I første afsnit taler Lucia Odoom med panelet om, hvilke sange der perfekt afspejler forårets romantiske energi og hvilke forårsfortsæt panelet har. I andet afsnit, som udkommer i påskeferien, skal vi tale om den svære spirende kærlighed, og hvordan vi dater uden datingapps. Producer: Sille Westphal Panel og anbefalinger: Jesper Binzer, forsanger i D-A-D og forfatter til ’Flot kronhjort’, anbefaler kvindelig black metal som ’Witch Club Satan’, ’Konvent’ og ’Vulvatorious’ Johanne Bille, forfatter og journalist, anbefaler ’kvinderne i fængslet’ Mads Axelsen, radiovært og PR- og kommunikationsanvarlig på Blagaard Teater, anbefaler at høre Liss og mindes Søren Holm Vært Lucia Odoom anbefaler Bad Bunny’s tiny desk koncertSee omnystudio.com/listener for privacy information.

Learning and applying God's 10 problem-solving devices will fortify the FLOT line in your soul (FLOT is an acronym for Forward Line of Troops), preventing the outside sources of adversity from becoming the inside pressure of stress in your soul. This episode (Part 2) covers the fourth and fifth devices: 4. Grace Orientation (understanding God's policy for salvation, living, dying, and eternity) and 5. Doctrinal/Biblical Orientation (knowing every problem in life has a solution stated in the Word of God). You glorify God when you use God's spiritual assets to solve all your daily problems.Download Transcript: https://rhem.pub/problem-solving-68cf65

Learning and applying God's 10 problem-solving devices will fortify the FLOT line in your soul (FLOT is an acronym for Forward Line of Troops), preventing the outside sources of adversity from becoming the inside pressure of stress in your soul. This episode (Part 1) covers the first PSDs: 1. Rebound (how to handle personal sin), 2. Filling of the Holy Spirit (how to empower your spiritual life), and 3. Faith-Rest Drill (how to address worry, fear, and anxiety). You glorify God when you use His spiritual assets to solve all your daily problems.Download Transcript: https://rhem.pub/problem-solving-ac9077

Welcome to another episode of the Oncology Brothers! In this episode, Drs. Rahul and Rohit Gosain are joined by their brother, Dr. Timothy Brown from UT Southwestern, to discuss the latest treatment paradigms for upper gastrointestinal (GI) malignancies, specifically focusing on esophageal and gastroesophageal junction adenocarcinoma, as well as gastric cancer. Episode Highlights: •⁠  ⁠Early Disease Management: perioperative FLOT versus concurrent chemoradiation. •⁠  ⁠Adjuvant Nivolumab: Insights from the Checkmate 577 trial and its implications for patients with residual disease post-chemoradiation. •⁠  ⁠Biomarker Testing: The importance of testing for MSI, HER2, Claudin 18.2, and PD-L1 to guide treatment decisions in metastatic settings. •⁠  ⁠Patient-Centered Care: Emphasizing the significance of shared decision-making and multidisciplinary approaches in managing complex cases. Join us as we unpack the nuances of upper GI malignancies and share key takeaways from recent studies and clinical practices.  YouTube: https://youtu.be/UNyi71u2wIw Follow us on social media: •⁠  ⁠X/Twitter: https://twitter.com/oncbrothers •⁠  ⁠Instagram: https://www.instagram.com/oncbrothers •⁠  Website: https://oncbrothers.com/ Don't forget to like, subscribe, and hit the notification bell for more updates on treatment algorithms and oncology insights!  

Angoissé par l'actu morose et surtout le flux d'infos bazardées à longueur de journée ? Bonne nouvelle, on a des pistes pour faire baisser la pression (et de bonnes suggestions lectures) :Optez pour des médias constructifs : qui offrent une vision de l'info à 360 degrés, nuancées en ne misant pas tout sur des titres racoleurs, sensationnalistes, polarisants.Tournez vous vers des contenus porteurs de solutions qui vous permettront de transformer votre angoisse en actionChoisissez des moments précis pour vous informer, supprimez les push pour arrêter la perfusion et éviter l'inforexie et l'infobésité.Gardez et cultivez votre esprit critique, prenez de la hauteur, remettez les choses en contexte et tentez de relever le débat en vous entourant d'avis différents et argumentés.N'oubliez jamais que s'il y a plein de choses qui ne vont pas, il y a aussi plein de choses qui vont bien.Soyez conscients de la manière dont fonctionnent les médias et les réseaux sociaux grâce à ces livres très instructifs qui offrent des pistes de réflexion et de solution :Les médias, le monde et moi de Anne-Sophie NovelFactfullness de Hans RoslingYou are what your read de Jodie JacksonConstructive News de Hulrik HaagerupVous aimez ce contenu ? Alors n'hésitez pas à vous abonner, à lui donner des étoiles et à partager ce podcast autour de vous. Ça nous aide à nous faire connaitre et à essaimer les idées constructives qui rendent le monde plus joli !Une chronique signée Leslie Rijmenams à retrouver (aussi) sur Nostalgie et www.nostalgie.be.

Lyt til prædiken fra Gudstjeneste d. 9/3 2025.

Vil du eller kender du nogen, der kunne finde på at blive prtner på en eller flere udsendelser fra Kvart i bold. Så skriv til kvartiboldinfo@gmail.com.Du kan også støtte os ved at melde dig ind her: https://kvartibold.memberful.com/join Hosted on Acast. See acast.com/privacy for more information.

EFTER F.C. KØBENHAVN-CHELSEA: ÆRGERLIGT RESULT PÅ FLOT INDSATSØv øv øv… 1-2 mod Chelsea efter en absolut godkendt indsats i Parken.Copenhagen Sundays' Mathias Aw og David E. Bastian-Møller runder her aftenens kamp af.Prod.: Copenhagen Sundays.Partner: Unibet.#fcklive #uecl #sldk #parken #fck #copenhagensundays #fckøbenhavn #superligaenEn special fra Sundays Podcast – podcast fra Copenhagen Sundays.

Vil du eller kender du nogen, der kunne finde på at blive prtner på en eller flere udsendelser fra Kvart i bold. Så skriv til kvartiboldinfo@gmail.com.Du kan også støtte os ved at melde dig ind her: https://kvartibold.memberful.com/join Hosted on Acast. See acast.com/privacy for more information.

W najnowszym odcinku: Rosja: nacjonalizacja przedsiębiorstw, flota cieni i pracownicy z Korei Północnej Klimat: pękający lód Grenlandii i zagrażające życiu upały Wyzwania humanitarne: utrata funduszy, zbrodnie i przemoc gangów Problemy gospodarcze Kanady, Niemiec i Chin Odporność na demencję i ultradźwięki przeciwko depresji Kobiety-twórczynie w sztuce: Afryka Zachodnia i szekspirowska Anglia Niezależność energetyczna, sojusz pronuklearny i „zielony” wodór Oburzenie we Włoszech i masowe groby w Libii

Les chiffres de la croissance pour 2024 sont publiés ce vendredi. L'occasion de nous intéresser à ce qui fait respirer cette économie russe, à savoir les hydrocarbures, puisque le pétrole et le gaz sont les deux poumons du pays. Décryptage.   La Russie fait partie des trois principaux producteurs de pétrole au monde avec l'Arabie Saoudite et les Etats-Unis. Les hydrocarbures sont donc essentiels à son économie. En valeur, ils représentent pratiquement la moitié de ses exportations. Preuve de leur importance: en 2021, avant l'invasion de l'Ukraine et les sanctions occidentales donc, ils représentaient 46% du budget russe. C'est donc un apport de devises très important pour Moscou. Pour autant, les sanctions occidentales n'ont pas eu d'impact aussi fort sur l'économie russe que l'auraient espéré les pays occidentaux. Les exportations d'hydrocarbures russes ont tendance à légèrement diminuer mais c'est vraisemblablement lié à la baisse d'achat de charbon. En revanche, le pétrole et le gaz en volume restent stables. Des sanctions pas assez fortes On peut voir deux raisons à la stabilité des exportations de pétrole et de gaz. D'une part, les sanctions occidentales ne sont pas assez fortes pour toucher le cœur du système russe. Et si elles ne sont pas assez mordantes, c'est surtout pour éviter de déstabiliser les marchés occidentaux. D'autre part, la Russie a réorienté ses exportations. Fini l'Ouest et les Occidentaux. Maintenant, direction l'Asie avec surtout l'Inde et la Chine qui sont deux grands clients de Moscou. Petite subtilité, la Russie a augmenté ses taxes sur les exportations pour compenser les pertes occidentales. Pourtant les économies occidentales semblent s'être habituées à vivre avec moins d'hydrocarbures russes et à long terme, ça aura des conséquences sur la Russie. À lire aussiFaible croissance, hausse des prix, la Russie face au risque de stagflationPoint de bascule Ces sanctions commencent à avoir un impact notamment sur le pétrole. S'il y a un prix maximal de 60 dollars imposé par les Occidentaux pour l'achat de barils, les Russes réussissent à contourner la mesure avec leur flotte fantôme. Il s'agit là de vieux cargos clandestins pleins de pétrole qui font le tour du monde pour trouver preneurs. Ça, ça compte, puisque d'après l'école d'économie de Kiev, près de 90 % du brut russe se négocie au-dessus de ce plafond, ce qui représente une marge de 10 milliards de dollars par an.À lire aussiSécurité maritime: pourquoi la «flotte fantôme» russe échappe-t-elle à tout contrôle? Les hydrocarbures russes ont, pour le moment, de beaux jours devant eux. Mais c'est sans compter sur Donald Trump. Le président américain entend bien mettre la pression sur Moscou. Il compte tout simplement utiliser ces hydrocarbures comme arme géopolitique. Sa solution : demander aux pays exportateurs de pétrole comme l'Arabie saoudite de produire plus, ce qui engendrera mécaniquement une baisse des prix. Et donc pour que la Russie continue de vendre, elle devra, elle aussi, baisser ses prix pour être compétitive.  L'idée fait son chemin car elle pourrait frapper très fortement Moscou au portefeuille puisque la Russie ne peut pas se passer de ses exportations pour soutenir son économie. Le tout dans un contexte de surchauffe de son économie de guerre. La croissance portée par les dépenses dans l'armement se tarit de plus en plus. Cela veut dire que si cet autre pilier de l'économie russe est vacillant sur le long terme, en plus d'une baisse du prix du pétrole, ça va compliquer les affaires de Moscou. L'industrie militaire deviendrait alors investissement peu rentable. Car finalement, produire un char qui se fera détruire en Ukraine n'a pas la même valeur qu'exporter plusieurs millions de barils de pétrole par jour ! 

Dr. Shaalan Beg and Dr. David Wang discuss key abstracts in GI cancers from the 2025 ASCO Gastrointestinal Cancers Symposium, including major advances in CRC, neoadjuvant approaches in esophageal cancer, and innovative studies on ctDNA. TRANSCRIPT Dr. Shaalan Beg: Hello and welcome to the ASCO Daily News Podcast. I'm Dr. Shaalan Beg. I'm a medical oncologist and an adjunct associate professor at UT Southwestern Medical Center in Dallas. Today, we're bringing you some key highlights from the 2025 ASCO Gastrointestinal Cancers Symposium, and I'm delighted to be joined by the chair of GI25, Dr. David Wang. Dr. Wang is a GI medical oncologist at the University of Michigan. Our full disclosures are available in the transcript of this episode.  Dr. Wang, thanks for coming on the podcast today. Dr. David Wang: Well, thank you. It's a pleasure to be here. Dr. Shaalan Beg: GI25 featured major therapeutic advances across the spectrum of GI malignancies, and it was exciting to hear about innovations and novel approaches that are shaping the future of our field. Before we start talking about specific abstracts, could you share some of your key highlights from the meeting? Dr. David Wang: Sure. Our theme this year was “Breaking Boundaries to Enhance Patient Centered Care.” Past years' themes have focused more on precision oncology, but we wanted to broaden our focus on patients and to be more holistic, which kind of led us into some of the Intersection [sessions] that we had. Each day started with a different Intersection. The first one was “Emerging Therapies in GI Cancers”, where invited speakers talked about bispecific antibody drug conjugates, theranostics, CAR T and other cell-based therapies. The second day was on “Personalized Risk Assessment for GI Cancers,” and this included looking at polygenic risk scores for colorectal cancer, microRNAs and liquid biopsies such as exosomes and pancreatic cancer and non-endoscopic screening modalities in esophageal cancer. And on our final day, we wanted to talk about “Integrative Oncology and Integrative Medicine,” looking at evidence-based uses of acupuncture and supplements in patients who are receiving treatment for cancer, mindfulness-based practices and exercise. And of course, we had a fantastic keynote talk by Dr. Pamela Kunz from the Yale School of Medicine titled, “Disrupting Gastrointestinal Oncology: Shattering Barriers with Inclusive Science.” She highlighted the intersection of science, patient care, and health and gender equity. And I would encourage your podcast listeners to access the lecture in ASCO's Meeting Library if they haven't yet had a chance to hear Dr. Kunz's wonderful lecture.  We were really happy this year because the attendance hit a new record. We had over 5,000 people attend either in person or virtually from their home or office, and we had almost 1,000 abstracts submitted to the meeting, so these were either record or near record numbers. We offered a lot of different networking opportunities throughout the meeting, and attending found these to be incredibly rewarding and important and this will continue to be an area of emphasis in future meetings. Dr. Shaalan Beg: Let's take a deeper dive into the exciting studies presented at GI25. The late breaking abstract LBA143 was CheckMate-8HW. This was the first results of NIVO + IPI versus NIVO monotherapy for MSI-high metastatic colorectal cancer. What are your thoughts about this study? Dr. David Wang: Yeah, so we know that colorectal cancer patients with MSI-high tumors don't necessarily respond well to chemotherapy. And we were fortunate because last year CheckMate-8HW actually looked at two different arms – so this was NIVO + IPI compared to standard of care chemotherapy and showed its very significant improvement in median progression-free survival. And that was actually published in the New England Journal of Medicine back in November of 2024. This year's presentation actually focused now on NIVO + IPI versus NIVO monotherapy. And as you know IPI+NIVO can be quite toxic. So this was an important analysis to be done. So we know that NIVO is definitely more easily tolerated. So what was interesting was that the 2-year and 3-year progression-free survival not surprisingly favored IPI+NIVO and this was statistically significant. And the overall response rate was also better with IPI+NIVO versus NIVO alone. I know we're always concerned about toxicities and there were higher grade 3 and 4 toxicity incidences in the combination arm versus the monotherapy arm, but overall, only about 28 additional events in several hundred patients treated. So I think that's well-tolerated. Our discussant Dr. Wells Messersmith actually said that, with this new data, he would consider doing combination immunotherapy in any patient that presented in the front line with MSI-high or deficient mismatch repair colorectal cancer that was metastatic. Dr. Shaalan Beg: One of the focuses for directing first-line therapy for colorectal cancer has been right and left sided colon cancer because we know these are two different cancers with their own unique molecular subtypes. We heard on Abstract 17, the DEEPER trial, the final analysis of modified FOLFOXIRI plus cetuximab versus bevacizumab for RAS wild-type and left sided metastatic colorectal cancer. How do you summarize the findings of this study and what should our readers be aware of? Dr. David Wang: Interestingly, this was a phase 2 study and the emphasis of the abstract was actually a subgroup analysis of those patients with RAS wild-type and BRAF wild-type as well as left sided cancers. So, I think the entire study enrolled 359 patients, but the analysis that was discussed at the meeting really focused on 178 patients that fit that characteristic. Very similar to what we've seen in prior studies, left-sided tumors have better response to cetuximab versus bevacizumab. And if you flip it so that you now are looking at right sided tumors, targeting EGFR is actually detrimental. The depth of response was better with cetuximab in these left sided RAS and BRAF mutant tumors. And so the lead author actually suggested that this could be a new first-line standard of care. And the question is, is there a benefit of doing this triple agent regimen with modified FOLFIRINOX? We know there's a lot more toxicity with that. Not clear that there's a benefit for that over FOLFOX, maybe in younger patients that could tolerate it. When our discussant, again Dr. Wells Messersmith, spoke about this, he said that, in his practice he would, again, favor cetuximab over bevacizumab in combination with chemo, these left-sided RAS and BRAF wild-type tumors, but that he would actually prefer a doublet versus a triplet chemo regimen, and that is consistent with the current NCCN guidelines. Dr. Shaalan Beg: Another area where colorectal cancer has been a wonderful model to study new technology has been in the area of circulating tumor DNA (ctDNA). And the BESPOKE CRC trial is looking to see if ctDNA can inform adjuvant treatment decisions for stage II and III colorectal cancer. And in Abstract 15, we heard final results of the BESPOKE CRC sub-cohort. What were the findings there? Dr. David Wang: BESPOKE CRC is another one of these important ctDNA studies. It was an observational study, not a randomized trial, but it did provide a lot of different insights to us. We know that there were over 1,700 patients enrolled, and so it was reported that this is the largest ctDNA study in colorectal cancer performed in the United States. And they were able to analyze over 1,100 patients.  Some of the key findings were that postoperative adjuvant therapy management decisions actually changed in 1 out of 6 patients, so that's pretty significant. In terms of surveillance, we know that patients who have ctDNA positivity, this is prognostic of recurrence. In terms of patients who have positive ctDNA post-surgery, it looked like, at least in this observational study, the majority of patients who received any benefit were those who had positive ctDNA. So adjuvant therapy, even in stage II and stage III patients seemed to only benefit those patients who have positive ctDNA. I think that does raise the question, and this also was brought up in the discussion, which is “Can we de-escalate adjuvant therapy in terms of patients who are ctDNA-negative post-op?” And Dr. Richard Kim from Moffitt felt that we are not yet there. Obviously, we need randomized control trials where we are taking ctDNA results and then randomizing patients to receive adjuvant or non-adjuvant to really know the difference.  Other questions that come up with use of ctDNA include: What do you do with these patients who turn positive? This study for BESPOKE actually followed patients out to two years after surgery. So what you do with a positive ctDNA result wasn't really clear. It seems to suggest that once you turn positive, patients go on to more intensive surveillance. You know, again as an observation, patients who did turn positive were able to go to metastasis-directed therapy much more quickly. And again, this was supposedly to improve their curative intent therapy. And I think the other question that has been brought up all the time is, is this really cost effective? Patients want to know, and we want to give patients that information, but I think we're still stuck with what to do with a positive ctDNA level in a patient that's on surveillance because no randomized control studies have actually suggested that we need to start systemic therapy right away. Dr. Shaalan Beg: Yeah. And I guess in terms of practice informing or practice changing, these results may not give us a clear answer. But because a lot of patients are asking for these tests, it does give us some real world experiences on what to expect in terms of conversion of these positive into negative and the outcome so we can have a shared decision making with our patients in the clinic and then come up with a determination on whether ctDNA for molecular residual disease is something which would be worthwhile for the care of our patient. But more to come, I guess, in coming years to answer different problems around this challenge. Dr. David Wang: Yes, I agree. Dr. Shaalan Beg: The BREAKWATER trial looked at the use of encorafenib, cetuximab and chemotherapy for BRAF V600E-mutant metastatic colorectal cancer. We've covered this combination for a second- third-line treatment in metastatic colorectal cancer previously. Abstract 16 from GI25 was evaluating the use of this regimen in the first-line space. Everyone was looking forward to these results, and what did the investigators present? Dr. David Wang: I think this is, as you mentioned, a nice follow up to later lines of therapy where Dr. Kopetz from MD Anderson pioneered use of encorafenib, cetuximab and binimetinib in the BEACON trial. Everybody was kind of curious what would happen now if you use encorafenib plus cetuximab plus chemotherapy in the first-line setting. And so this is an interim analysis that was pre-planned in the phase 3 open label BREAKWATER trial. And even though there were three arms, and so the three arms were encorafenib plus cetuximab, encorafenib plus cetuximab plus FOLFOX, or standard of care chemo, only two arms were presented in the abstract. So basically looking at encorafenib plus cetuximab and FOLFOX-6 versus standard of care therapy, and the overall response rate was statistically significant with a 60.9% overall response rate encorafenib plus cetuximab plus chemo arm versus standard of care chemo was only 40%. The interim overall survival also was different. It was 92% versus 87% at 6 months and 79% versus 66% at 12 months, again favoring the chemotherapy plus encorafenib plus cetuximab. In terms of the statistics, the p was 0.0004. However, the pre-plan analysis required the p-value to be 1x10 to the -8. And so even though this looks really good, it hasn't quite met its pre-specified significance level. The good thing is that this is only interim analysis and the study is ongoing with future analysis planned.  So the real question is: Does it matter when we actually use this regimen? We know that the regimen's approved in the second third-line setting. What about in the first line? And there was some preclinical data that the discussant reviewed that shows that patients actually benefit if this is done in the first-line setting. For example, there was some preclinical data showing that even FOLFIRI, for example, can upregulate RAS, which would make tumors more resistant to this combination. This was thought to be practice-changing in a patient that has B600E showing up treatment naive that we should probably consider this regimen. And actually this did receive accelerated FDA approval about a month ago. Dr. Shaalan Beg: Yeah, and for what it's worth, I put up a Twitter poll asking my Twitter followers on how the BREAKWATER trial results will change their approach for newly diagnosed BRAF mutated colorectal cancer. We got 112 responses; 72% said that they will incorporate encorafenib, cetuximab, FOLFOX for their frontline BRAF mutated patients. But 23% said that they would like to wait for overall survival results. Dr. David Wang: Wow, that's interesting. They really want that 1x10 to the -8. Dr. Shaalan Beg: I guess so. All right. Let's change gears and talk about esophageal cancer. LBA329 was the SCIENCE study which presented preliminary results from a randomized phase 3 trial comparing sintilimab and chemoradiotherapy plus sintilimab versus chemoradiotherapy for neoadjuvant resectable locally advanced squamous esophageal cancer. Where are we in this space? Dr. David Wang: Okay. So, yeah, this was an interesting trial. Again, just to set the context, esophageal squamous cell carcinoma is more prevalent in Asia. And the study sites as well as the patients were mostly from Asia. So this was again a phase 3 trial with interim results. They only rolled 146 out of the planned 420 for this interim analysis. And yeah, they're using immune checkpoint inhibitor that we don't use in the United States, sintilimab, combined with their two standards of neoadjuvant therapy, either chemotherapy, which is more common in Asia, or or chemoradiation, which is more common in the US and Western Europe, versus chemoradiation. And so they actually had two primary endpoints, but only were reporting one. So their two primary endpoints were pathCR and the other one was event-free survival. The event-free survival, again, was not reported at the meeting.  What they found was that in terms of pathCR rate, if you take the two arms that are really informative about that, chemoradiation plus sintilimab versus chemoradiation alone, the pathCR rate was 60% versus 47%. We know that chemo alone doesn't induce as much of a pathCR rate, and that was 13%. So it was found that the delta in terms of pathCR between the chemoradiation arms, one with sintilimab and one without, was significant. And this actually confirms data again from Asia, like for the ESCORT-NEO trial where it used another immune checkpoint inhibitor pembrolizumab in addition to neoadjuvant chemo.  So as our discussant for this abstract said, yes, we know that radiation combined with chemotherapy improves pathCR rates, but we have recent data from the ESOPEC trial, we don't know that that necessarily will translate to overall survival. So again, waiting for additional enrollments and longer term follow up before incorporating this into clinical care here. Dr. Shaalan Beg: So David, how do the results of the SCIENCE trial compare with our practice in the United States and ongoing studies asking questions for neoadjuvant therapy for esophageal carcinoma in the United States? Dr. David Wang: I think obviously immune checkpoint inhibitor in the new adjuvant setting is important. Jennifer Eads at UPenn is running that EA2174 which is looking at chemoradiation plus or minus nivolumab, and then in non-pathCR responders randomized to adjuvant nivolumab per CheckMate 577 or nivolumab with intensification adding ipilimumab. We know that the ESOPEC trial just came out, and was published actually during the meeting, and that really focuses on adenocarcinomas. So adenocarcinomas of the GE junction, distal esophagus, now, we would probably treat very similarly to gastric using perioperative FLOT. However, the standard in the US for esophageal squamous cell carcinoma remains neoadjuvant chemoradiation. We know that squamous cell carcinomas are more exquisitely sensitive to radiotherapy. And then obviously in those patients who don't achieve a pathologic complete response, the expectation would be that they would go on to receive nivolumab per CheckMate 577. Again, the thought is that these tumors are more sensitive to immunotherapy given their higher incidences of mutational changes. And so again, this kind of goes along with the positive results seen in the SCIENCE trial that we just discussed with sintilimab but also EFFECT-neo with pembrolizumab. Obviously, we await the results of Jennifer's trial. Dr. Shaalan Beg: And the last abstract I was hoping we could get your perspective on was Abstract 652, which is a Phase 3 study of everolimus plus lanreotide versus everolimus monotherapy for unresectable or recurrent gastroenteropancreatic neuroendocrine tumors, the STARTER-NET trial. What were the results of this study? Dr. David Wang: So, I just want to give a shout out because we did have a session at this year's GI ASCO that looked at more rare tumors. So appendiceal tumors, neuroendocrine tumors, those kinds of things. So again, I would encourage your listeners to listen to that session if they have interest in that. Another type of rare tumor was adenosquamous tumors.  But in terms of the STARTER-NET trial, this was again an interim analysis of his phase 3trial and it was looking at combining everolimus plus lanreotide versus everolimus. So we know that in pancreatic-gastric neuroendocrine tumors, if you have low Ki-67, a well differentiated tumor, that the standard of care really is a somatostatin analog, and sometimes if they're more aggressive, we kind of consider molecular targeted therapy with everolimus. This was asking the question of whether we should do the combination on the frontline. And what was interesting is in this study, the patients were actually more of a poor prognostic set. So they had Ki-67 up to 20% or these were patients that actually had multiple liver lesions. And what they found was a median for progression free survival was improved with a combination out to 29.7 months versus 11.5 months with the somatostatin analog alone, and that the overall response rate was 23% versus 8.3%, again, favoring the combination. If you looked at subgroup analysis, it was actually those patients who had Ki-67 greater than 10%, so the more aggressive tumors, or those with diffuse liver lesions that had the most benefit. So I think that would be the patient population I would consider this new combination with using would be those patients again with poorer prognosis neuroendocrine tumor phenotype. Dr. Shaalan Beg: Thank you very much, Dr. Wang, for sharing your insights with us today and your great work to build a robust GI Cancers Symposium this year. Dr. David Wang: Well, thank you. I mean that really is a cooperative effort. We appreciate all the members of the GI25 Program Committee as well as the ASCO staff that just made it an outstanding meeting. Dr. Shaalan Beg: And thank you to all our listeners for your time today. You'll find links to the abstracts discussed today on the transcript of this episode.  Finally, if you value the insights that you hear on the ASCO Daily News Podcast, please take a moment to rate, review and subscribe wherever you get your podcasts. Disclaimer: The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions.  Guests on this podcast express their own opinions, experience and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity or therapy should not be construed as an ASCO endorsement. Find out more about today's speakers:  Dr. Shaalan Beg @ShaalanBeg  Dr. David Wang Follow ASCO on social media:   @ASCO on Twitter  @ASCO on BlueSky ASCO on Facebook   ASCO on LinkedIn   Disclosures:  Dr. Shaalan Beg:  Employment: Science 37  Consulting or Advisory Role: Ipsen, Array BioPharma, AstraZeneca/MedImmune, Cancer Commons, Legend Biotech, Foundation Medicine  Research Funding (Inst.): Bristol-Myers Squibb, AstraZeneca/MedImmune, Merck Serono, Five Prime Therapeutics, MedImmune, Genentech, Immunesensor, Tolero Pharmaceuticals  Dr. David Wang: Honoraria:  Novartis Consulting or Advisory Role: Novartis, Cardinal Health, Bristol-Myers Squibb, BeiGene, Eisai  

Mecenasi programu: ChatLab ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠www.chatlab.pl ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ Ekovolits: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://ekovolits.pl ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ (00:00) Wstęp (1:17) Unia Europejska nałożyła nowe sankcje na rosyjską „flotę cieni” (2:49) Dyrektor amerykańskiego FBI zrezygnuje przed objęciem prezydentury przez Donalda Trumpa (4:00) Niemcy zamierzają umożliwić syryjskim uchodźcom „dobrowolny i bezpieczny” powrót do ojczyzny (5:31) Wielka Brytania bezterminowo zakazała podawania nieletnim blokerów dojrzewania w celu zmiany płci (6:49) Rumuńskie partie pro-zachodnie zawarły koalicję rządową i wyłonią wspólnego kandydata w wyborach prezydenckich (8:18) SpaceX stało się najdroższym start-upem na świecie (9:42) FIFA ogłosiła gospodarzy dwóch turniejów mistrzostw świata Informacje przygotował Maurycy Mietelski. Nadzór redakcyjny – Igor Janke. Czyta Michał Ziomek

W jaki sposób firmy

SUNDAYS PODCAST #128: ØV, ØV, ØV – PLADS TIL FORBEDRING… Tung fredag morgen… “Jeg er træt af, at går ind i Parken i godt humør, og gå ud igen i dårligt,” sådan skrev en bruger i redaktørens feed, da han kl. 01.30 torsdag nat kom hjem fra netop Parken. Det kører ikke på banen for F.C. København. Ikke i superligaen og slet ikke i europa. Ikke på hjemmebane i hvert fald. Det – og meget andet – skal vi tale om denne fredag. Nyheder fra FCK-land, 25 år er gået, ugens store historie og ugens spiller.  Tidskoder: 00:39  Intro og hej! 02:49  Sidste nyt: Flot delårsregnskab, Silkeborg-kampen, Buur, Kvinderne, Skændsel i Amsterdam og græsset. 34:05  ProTreatment 35:07  25 er gået: Derby. 38:12  Ugens store historie: Øv, øv, øv – plads til forbedring 1:04:37  Ugens spiller: Fed energi… Støt Copenhagen Sundays! Vi taler også om vores støtte/medlemskoncept. Det kan du læse mere om her: https://copenhagensundays.memberful.com/join Episoden er optaget i Parken, torsdag den 8. november 2024. Værter: Rasmus Kaas, Michael Rachlin og David E. Bastian-Møller. Sundays Podcast. Episode #128. Podcast fra Copenhagen Sundays.

Nu kan du møde Heidi Van Fliet, hun er 19 år bagerlærling hos Konditorbageren i Outrup, i denne uge var hun en tur i KBH, men hvad skete der, derover.

In this episode, we review key components of the landmark MAGIC and FLOT-4 trials that investigated perioperative chemotherapy in the treatment of locally advanced gastric cancer.  We discuss limitations of both trials and the evolving clinical landscape of gastric cancer treatment. Hosts: - Timothy Vreeland, MD, FACS (@vreelant) is an Associate Professor of Surgery at the Uniformed Services University of the Health Sciences and Surgical Oncologist/HPB surgeon at Brooke Army Medical Center. - Daniel Nelson, DO, FACS (@usarmydoc24) is a Surgical Oncologist/HPB surgeon at Kaiser Permanente Los Angeles Medical Center. - Connor Chick, MD (@connor_chick) is a Surgical Oncology Senior Fellow at Ohio State. - Lexy (Alexandra) Adams, MD, MPH (@lexyadams16) is a Surgical Oncology Junior Fellow at MD Anderson Cancer Center. - Beth (Elizabeth) Barbera, MD (@elizcarpenter16) is a PGY-6 General Surgery resident at Brooke Army Medical Center.  Learning Objectives:  1.     Understand background, methodology, results, and interpretation of the MAGIC trial. 2.     Understand background, methodology, results, and interpretation of the FLOT trial. 3.     Be able to discuss the evolution of chemotherapeutic regimens in the treatment of locally advanced gastric cancer and rationale for their use. 4.     Be able to describe key limitations for the above regimens. 5.     Discuss the the evolving clinical landscape for chemotherapy in gastroesophageal junction tumors. Links to Papers Referenced in this Episode: Journal Articles: Cunningham, D., Allum, W. H., Stenning, S. P., Thompson, J. N., Van de Velde, C. J., Nicolson, M., ... & Chua, Y. J. (2006). Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. New England Journal of Medicine, 355(1), 11-20. https://pubmed.ncbi.nlm.nih.gov/16822992/ Al-Batran, S. E., Homann, N., Pauligk, C., Goetze, T. O., Meiler, J., Kasper, S., ... & Hofheinz, R. D. (2019). Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trial. The Lancet, 393(10184), 1948-1957. https://pubmed.ncbi.nlm.nih.gov/30982686/ Please visit https://behindtheknife.org to access other high-yield surgical education podcasts, videos and more.   If you liked this episode, check out our recent episodes here: https://app.behindtheknife.org/listen

Trois jours après l'attaque massive de missiles lancée par l'Iran contre Israël, les images de cette nouvelle montée des tensions sont partout sur les réseaux sociaux. Dans ce contexte, un flot d'images sorties de leur contexte circule encore activement. Dès les premières minutes de cette attaque, des comptes influents ont diffusé massivement des fausses informations, à tel point qu'il est encore difficile de démêler le vrai du faux. Tout commence au moment même où l'armée israélienne annonce que des missiles viennent d'être tirés depuis l'Iran. Pendant que les sirènes d'alerte retentissent en Israël, une première vidéo devient virale sur les réseaux sociaux. On y voit des dizaines de camions lance-roquettes multiples, parfaitement alignés, à flanc de colline, en train de lancer des centaines de projectiles dans le ciel. Des internautes affirment que ces images impressionnantes montreraient la pluie de missiles lancées par l'Iran en direction d'Israël. Certains vont même jusqu'à dire, à tort, que la télévision iranienne aurait diffusé cette séquence.Sauf que vérification faîte, ces images ne sont pas réelles. Cette vidéo, apparue pour la première fois en ligne sur TikTok en novembre 2023, est tirée d'un jeu vidéo. L'analyse des graphismes et des camions lance-roquettes, des M-77 Oganj de fabrication yougoslave, montre que cette scène est issue d'un jeu de simulation militaire baptisé Wargame : Red Dragon.D'autres images de ce type circulent ces derniers jours. Après que les premiers missiles ont frappé Israël, certains ont diffusé une vidéo censée montrer un avion iranien attaquant Tel Aviv.Mais là encore, cet extrait est issu d'un jeu vidéo. Aucun avion iranien n'a attaqué Israël. Ces images de synthèse sont destinées à faire du clic et à semer la terreur.Benyamin Netanyahu ciblé par les infoxPour faire croire à des scènes de paniques sans précédent en Israël, certains partagent une vidéo dans laquelle on voit, Benyamin Netanyahu, courir dans un couloir. Ceux qui la diffusent affirment qu'elle montre le premier ministre israélien, en panique, en train de se réfugier dans son bunker présidentiel.Sauf qu'une nouvelle fois, c'est faux. La vidéo en question a été diffusée par Benyamin Netanyahu lui-même sur son compte X (ex-Twitter), le 13 décembre 2021. Il courrait alors dans les couloirs de la Knesset pour aller voter, et non pas pour se mettre à l'abri d'une attaque de missiles.Les images de dégâts, le vrai du fauxConcernant l'ampleur des dégâts sur le territoire israélien, une nouvelle fois, parmi les vraies images se cachent énormément de documents sortis de leur contexte. Une vidéo vue plus d' 1 600 000 fois prétend notamment montrer un missile frapper de plein fouet un immeuble résidentiel à Tel-Aviv.Une recherche d'image inversée montre pourtant qu'il s'agit d'un drone ukrainien percutant une tour à Moscou, en 2023. En plus de diffuser ces infox, les mêmes comptes affirment qu'Israël aurait recouvert l'une de ses bases militaires frappées par les Iraniens, avec des faux nuages pour empêcher les satellites de voir les dégâts.Une fausse information vue des millions de fois, démentie par les images satellites publiée ces dernières heures, et qui montre bien des dégâts, notamment sur la base de Nevatim.

Mon tout-petit, Ma toute-petite, viens te jeter dans Mes bras, pose ton coeur contre Le Mien... Reçois le flot de grâces et d'Amour que le Père déverse en toi en ce moment! Accueille-les pleinement; tu y trouveras la sécurité que tu cherches. Parce que l'Amour nous aime, nous devenons l'amour!

✨Bienvenue sur Grossesses d'Entrepreneuses✨Aujourd'hui, je vous propose, en lieu et place de nos habituelles interviews, une nouvelle “capsule conseil”. Le mois dernier, la capsule-conseil #1 sur le congé maternité vous avait beaucoup plus !Ce mois-ci, le sujet de cette nouvelle capsule-conseil m'a été soufflé par l'une d'entre vous, Julia, qui m'a écrit pour me dire :“Merci pour tout ce que tu as partagé sur le congé maternité, c'est tellement rassurant ! Pour ma part, ce n'est pas tant le côté administratif qui m'inquiète, mais l'impact sur mon business.Quelles stratégies me conseillerais-tu pour maintenir mon activité à flot pendant et après ma grossesse ?"Je partage ma réponse dans cet épisode !----------Les ressources mentionnées dans l'épisode :La formation en ligne Préparation Business à la Grossesse Téléchargez le guide gratuit "6 stratégies alternatives pour financer son congé mat'" ➡️guide gratuit----------Pourquoi “Grossesses d'Entrepreneuses” ?Grossesses d'Entrepreneuses est le premier podcast consacré aux stratégies entrepreneuriales lorsqu'on devient mère. Dans ce podcast, vous allez découvrir à chaque épisode l'histoire d'une entrepreneuse qui nous partage comment sa ou ses grossesses ont impacté son entreprise. Mon intention en faisant circuler ces retours d'expériences, tous aussi différents qu'inspirants, est de vous permettre de faire des choix éclairés afin que la grossesse soit synonyme d'opportunité pour votre business !Je suis Solène Pignet, votre hôte. Je suis moi-même cheffe d'entreprise depuis 2014 et autrice du Guide de l'Entrepreneur Durable publié aux éditions Dunod … que j'ai justement écrit pendant ma première grossesse. (Pour en savoir plus sur mon histoire, et la genèse de ce podcast, et ce qui m'a poussé à créer la Préparation Business à la Grossesse, je vous invite à écouter l'épisode 0 !) Je suis convaincue que la maternité peut être une force positive dans le développement de son activité - même quand tout ne se passe pas comme prévu - et c'est ce que je vous invite à explorer au fil des épisodes. Plus d'infos : www.grossessesdentrepreneuses.frRetrouvez-moi sur Instagram : www.instagram.com/solene.pignetOu LinkedIn : www.linkedin.com/in/sol%C3%A8ne-pignet/

Air Sénégal, la compagnie nationale, multiplie les trous d'air et les turbulences. Créée en 2016, elle s'est très rapidement retrouvée confrontée à de nombreux problèmes financiers qui ne cesse de s'aggraver. Sa dette est d'ailleurs estimée à 150 millions de dollars, selon l'État sénégalais. À cela s'ajoutent d'importants retards et des annulations. Dernière illustration de cette crise : la fermeture de plusieurs lignes, à partir de jeudi 19 septembre et les jours qui suivent. Malgré la matinée pluvieuse, le flot de clients est continu dans l'agence Air Sénégal du centre-ville de Dakar. Et lorsqu'on leur demande comment s'est passée leur dernière expérience, cela ressemble souvent à ce que décrit cet habitué de la compagnie, qui volait il y a quelques jours. « On n'a pas quitté à l'heure qui était prévue. On a eu quelque chose comme quatre heures de retard, regrette-t-il. Il faut qu'ils améliorent le système parce que beaucoup de gens ne sont pas contents. Il peut y avoir des aléas, mais il ne faut pas laisser les problèmes perdurer comme ça. »Autre client, cet homme d'affaires qui est venu s'assurer que son vol était maintenu. Pour lui, malgré les problèmes, pas question de délaisser Air Sénégal. « C'est ma compagnie nationale. Donc si la destination est desservie, vraiment, je préfère ma compagnie nationale », assure-t-il. « Si mon pays parvient à faire des efforts pour mettre en place une compagnie, c'est notre devoir de soutenir notre pays en empruntant cet avion malgré les péripéties », poursuit-il, convaincu.Réduire la dette couranteAir Sénégal met fin d'ici à la fin du mois à plusieurs liaisons vers New York, Douala ou encore Marseille et Lyon. La compagnie n'aura plus aucune route en dehors du continent africain à part celle vers Paris. Un sujet de préoccupation pour Abou Ba, le directeur général de Contact Voyages Sénégal, rencontré à un salon des professionnels du tourisme à Paris. « Cela nous inquiète beaucoup qu'Air Sénégal arrête certaines destinations parce que c'était une facilitation, témoigne le voyagiste. Cela nous permettait d'avoir beaucoup plus de monde, parce que cela permettait aux voyageurs, pas simplement depuis Paris, mais aussi depuis chaque région, de pouvoir voyager directement vers le Sénégal. C'était beaucoup plus facile. »La suppression de certaines dessertes présentées par la compagnie comme « une optimisation de son réseau » était pourtant inévitable vu sa situation économique. Grégory Venance est le directeur du cabinet d'expertise Aeroinflight et ancien employé d'Air Sénégal. « C'est un mal qui était nécessaire, estime-t-il. On est sûr des routes comme celles de New York qui perdent plus d'un million de dollars par mois. Et elles permettront certainement de réduire la dette courante qui dépasse les 5 millions par mois. Et c'est déjà un moindre mal. »« Il y a eu très peu de continuité »Au-delà, des destinations assurées à perte, l'achat de plusieurs avions neufs s'est également révélé être une très mauvaise opération financière, selon Grégory Venance. Pour lui, c'est le résultat de la valse des dirigeants à la tête de la compagnie. « Chaque directeur a complètement désavoué ce que le précédent a fait. Il y a eu très peu de continuité, parfois, il y a même eu des inepties de management entre deux directions et tout ceci a coûté énormément d'argent et beaucoup de temps. Et cela n'a pas permis à la compagnie de se positionner pour rebondir », décrypte-t-il.Début août, un nouveau directeur général, Tidiane Ndiaye, a été nommé. Selon le ministre des Transports El Malick Ndiaye sa vision correspond à celle des nouvelles autorités et sa mission est ni plus ni moins que de redresser durablement Air Sénégal.À lire aussiSénégal: le lancement du satellite Gaindesat-1A est «un gain de temps, d'énergie et d'argent»

Flot regnskab, skuffede investorer. Så kort kan regnskabet fra Nvidia opsummeres, men med så gigantiske forventninger, er det tilsyneladende svært ikke at skuffe i detaljen. Millionærklubben ser på ugens vigtigste regnskab sammen med Mads Christiansen, fondschef i New Deal Invest, og debatterer, om aktiekursudviklingen synes fair eller overdrevet. I studiet ser panelet, chefanalytiker Lau Svenssen fra Svenssen & Tudborg og Michelle Nørgaard fra Jyske Bank, på dagens åbningsniveauer og tjekker desuden de amerikanske forbrugeres lyst til fortsat at forbruge. Vært: Bodil Johanne Gantzel.  Producer: Kasper RiisingSee omnystudio.com/listener for privacy information.

The Accelerators (Drs. Matt Spraker and Simul Parikh) host Radiation Oncologists and elite GI educators Drs. Krish Jethwa and Nina Sanford.We discuss the exciting phase III ESOPEC study presented at ASCO 2024. The study demonstrated an overall survival benefit for perioperative FLOT chemotherapy versus pre-operative chemoradiation therapy for GE junction adenocarcinoma. Krish's ESOPEC thread on XNina's ESOPEC thread on XKrish on TAP discussing esophageal radiotherapy dosingASCO Daily News on the ESOPEC StudyThe FLOT4 StudyKeynote-585 StudyLatest publication from the DANTE trialMATTERHORN Trial at ESMO 2023ASCO Daily News on Keynote-585 and MATTERHORN (2024)The CheckMate 577 StudyCALGB 80803 (Alliance) Study"The Firefighter Study from the 70s" (1981)The Accelerators Podcast is a production of Photon Media, a division of the Cold Light Legacy Company.If you'd like to support our efforts, please visit the Cold Light Legacy Company to learn more.

Join Drs. Rohit Gosain and Rahul Gosain as they dive into the practice-changing updates from ASCO 2024 conference. In this episode, they are joined by Dr. Mark Lewis to cover key studies in GI malignancies from the conference. In this episode, they discuss: •⁠  ⁠The ESOPEC study comparing concurrent chemoradiation versus periop FLOT regimen for upper GI adenocarcinoma. •⁠  ⁠The ARMANI trial on switch maintenance with ramucirumab plus paclitaxel. •⁠  ⁠The TRANSMET trial exploring chemotherapy followed by liver transplantation for metastatic liver-confined colorectal cancer. •⁠  ⁠The COLLISION trial comparing surgery versus ablation for small size colorectal liver metastatic disease. •⁠  ⁠The COMMIT study looking at the use of atezolizumab with chemotherapy in first-line treatment for MSI high metastatic colorectal cancer. These studies highlight the importance of biomarker testing and a multidisciplinary approach in the treatment of cancer. Tune in to gain valuable insights from ASCO 2024 and stay informed about the latest advancements in oncology. Don't forget to check out their lung, GU, and breast cancer highlights from the conference as well. Stay connected with the Oncology Brothers for more updates and discussions on the latest in the world of oncology. Thank you for tuning in!

Dr. Shaalan Beg highlights practice-changing studies in GI cancers featured at the 2024 ASCO Annual Meeting, including the ESOPEC trial in esophageal adenocarcinoma and durable responses to PD-1 blockade alone in mismatch repair-deficient locally advanced rectal cancer. TRANSCRIPT Geraldine Carroll: Welcome to the ASCO Daily News Podcast. I'm Geraldine Carroll, a reporter for the ASCO Daily News. My guest today is Dr. Shaalan Beg, an adjunct associate professor at UT Southwestern Simmons Comprehensive Cancer Center. Dr. Beg will be discussing practice- changing abstracts and other key advances in GI oncology that were presented at the 2024 ASCO Annual Meeting. His full disclosures are available in the transcript of this episode.  Dr. Beg, thanks for being on the podcast today.  Dr. Shaalan Beg: Thank you for having me. Geraldine Carroll: Let's begin with LBA1, the ESOPEC trial. This was featured in the Plenary Session, and this study compared two treatment strategies for locally advanced esophageal adenocarcinoma that could be treated with surgery. The strategies include the CROSS protocol, which consisted of chemoradiotherapy before surgery, and the FLOT protocol of chemotherapy before and after surgery. Can you tell us about this practice-changing study, Dr. Beg? Dr. Shaalan Beg: Yes. According to this study, perioperative chemotherapy with FLOT was better than neoadjuvant therapy with chemoradiation and carbo-taxol for people with adenocarcinoma of the esophagus. There were 438 patients enrolled on this phase 3 study. R0 resection rates were fairly similar across both groups. The PCR rates were a little higher on the FLOT group. But when you look at the median overall survival difference, 66 months in the FLOT group versus 37 months in the CROSS group, 3-year survival was 57% versus 50% favoring FLOT therapy as well.  So a couple of caveats on this clinical trial, because the first thing to note is that the standard treatment for this disease has evolved because we now don't only give CROSS chemoradiation, we also give immunotherapy after the completion of chemoradiation for this group of patients. And in this study, since it predated that standard of care, patients did not receive immunotherapy. But having said that, the take home for me here is that chemotherapy is better than chemoradiation for this group of patients, recognizing the fact that 1) they only enrolled adenocarcinoma patients, and 2) patients with high T stage were not included. So the folks with high T stage would be those who we would expect would benefit from the radiation aspect. So my take home here is that more chemotherapy is better in the perioperative space. Radiation should be considered for individuals who need more local control. But in general, I think we're going to see us moving more towards chemotherapy-based regimens with FLOT for this group of patients. Geraldine Carroll: Great. So moving on to rectal cancer, in LBA3512, investigators reported durable, complete responses to PD-1 blockade alone in mismatch repair deficient locally advanced rectal cancer. Can you tell us more about the promising durable responses that occurred in this trial?  Dr. Shaalan Beg: On first glance, seeing that immunotherapy has good activity in patients with mismatched repair deficient rectal cancer isn't really headline breaking news anymore. We've known about this activity for this group of patients for many years. Earlier at ASCO, the investigators presented early results of this compound for people receiving six months of dostarlimab therapy for people with mismatched repair deficient, locally advanced rectal cancer, and showed that they had a very high complete response rate. At that time, it generated a lot of interest and there was a lot of curiosity on whether these outcomes will be sustained. We don't know other characteristics of their biologic status and whether this was some sort of reflection of the patients who are selected or not.   So here in this presentation at ASCO 2024, they did come back to present follow-up data for people with mismatch repair deficient colorectal cancer, having received 6 months of dostarlimab. Forty-seven patients had been enrolled, and the 41 patients who had achieved a clinical complete response continued to have disease control with no distant metastases. So that's very compelling information. There were no additional serious adverse events greater than grade 2 that they saw, and they did follow circulating tumor DNA, and those did normalize even before they had their colonoscopy to examine their tumors.  So, again, we're continuing to see very encouraging data of immunotherapy, and the response rate with dostarlimab seems to be very interesting for this disease, and it will be interesting to see how this pans out in larger studies and how this translates into the use of dostarlimab across other diseases where other checkpoint inhibitors are currently being used. Geraldine Carroll: Absolutely. So, moving on to LBA3501. The COLLISION trial looked at surgery versus thermal ablation for small cell colorectal liver metastases. This was an international, multicenter, phase 3, randomized, controlled trial. How will this study change clinical practice?  Dr. Shaalan Beg: Kudos to the investigators here. They looked to understand the difference in outcome in treating people with colorectal cancer with liver only metastases. These clinical trials are extremely difficult to design. They're very difficult to enroll on because of the multidisciplinary aspect of the interventions and patient and provider biases as well. So on this clinical trial, the investigators enrolled people with resectable colorectal cancer, liver metastases so they did not have any metastases outside the liver. Patients were required to have 10 or less known metastases that were less than 3 cm in size. There were other allowances for larger tumors as well. And after an expert panel review, patients were randomized to either resection or ablation. It was up to the physicians whether they performed these laparoscopically or openly or percutaneously, depending on the biology of the patient and the anatomical presentation.  There was a predefined stopping rule at the half-time for this clinical trial, which showed a benefit in the experimental arm of ablation compared to standard of care. The overall survival was not compromised. Progression-free survival was not compromised with local therapy. But there were differences in morbidity and mortality, as we would expect, one being a surgical procedure and the other being ablation, where, according to this study, of the 140 or so patients who received either treatment, 2.1% of people who underwent resection died within 90 days of surgery. The AE rate was 56% in the resection sample compared to 19% in ablation, and the 90-day mortality for ablation was 0.7%. So less morbidity, improved mortality, reduced adverse events with ablation versus surgical resection without compromising local control and overall survival.   And I think for practice here in the United States, this does provide very interesting data for us to take back to the clinic for lesions that are relatively small and could generally be addressed by both surgery and ablation. Historically, there are various non biologic factors that could go into deciding whether someone should have surgery or ablation, and it could be based on who the physician is, who's seeing the patient, what the practice patterns in a specific organization are, and where their expertise lie. But here we're seeing that ablation for the small lesions is a very effective tool with very good local control rates, and again, in this selected group of patients with liver only metastases. And I think it is going to make tumor board discussions very interesting with data backing ablation for these lesions. Geraldine Carroll: Well, let's move onto the MOUNTAINER study. This study created some buzz in the colorectal cancer space. That's Abstract 3509. Can you tell us about the final results of this phase 2 study of tucatinib and trastuzumab in HER2-positive metastatic CRC? What are your thoughts on this treatment option, which seems to be well tolerated? Dr. Shaalan Beg: So, HER2 overexpression or amplification occurs in about 3 to 5% of patients with metastatic colorectal cancer and up to 10% of people who have a RAS/RAF wild type disease. On the previous episodes of the podcast we have covered precision targeted therapy in colorectal cancer, focusing on c-MET, focusing on BRAF, and here we have updated results targeting HER2 for colorectal cancer. And the results of the MOUNTAINEER study have been out for a while. This is a phase 2 study looking at combining tucatinib which is a highly selective HER2 directed TKI with trastuzumab, the monoclonal antibody for HER2 targeting. And what they found on this study is the confirmed overall response rate was 38%. Duration of response was 12 months, overall survival was 24 months and these are the results that have been already released and now we have an additional 16 months of follow up and these results continue to hold on. PFS and overall survival gains were held, which makes it a very interesting option for people with colorectal cancer. You mentioned the tolerability aspect and side effects. I think it's important to know the spectrum of side effects for this disease may be a little different than other TKIs. There's hypertension, but there's also the risk of diarrhea, back pain and pyrexia, with the most common grade 3 treatment related adverse event was an increase in AST level seen in 10% of people of grade 3 and above.  So where does that really leave us? There is a confirmatory randomized first-line trial of tucatinib and trastuzumab in the first line setting, which is currently ongoing. So we'll stay tuned to see where that leads us. And with the HER2 space right now for colorectal cancer with the development of antibody drug conjugates, we may have more than one option for this group of patients once those trials read out. Geraldine Carroll: Excellent. Well, moving on to LBA4008, that's the CheckMate-9DW trial. This trial reported first results looking at nivolumab plus ipilimumab versus sorafenib or lenvatinib as first-line treatment for advanced hepatocellular carcinoma. Can you tell us about this trial? Will there be a potential new standard of care in advanced HCC? Dr. Shaalan Beg: When we think about patients with advanced HCC, the only treatment option that they had for about a decade and a half were just oral track tyrosine kinase inhibitors that had modest to moderate clinical activity. Since then, we've seen that combination therapy is better than TKI therapy, and the combination therapy has taken two different forms. One is a combination of checkpoint inhibitor and antiangiogenic therapy, such as in the combination of atezolizumab and bevacizumab. The other is a combination of dual checkpoint inhibitor therapy. Here we are talking about the results of nivolumab and ipilimumab. Previously, we've talked about the combination of durva and tremi for the treatment of patients with HCC.   So in this study, nivo was given for the first 4 cycles, nivo and ipi were given together, nivo 1 mg per kg, and IPI 3 mgs per kg every 3 weeks for 4 cycles. And then the CTLA-4 inhibitor ipilimumab was stopped. And this was followed by monotherapy nivolumab every 4 weeks until disease progression or up to 2 years. And it was compared to dealers' choice, lenvatinib or sorafenib. The median overall survival of nivo-ipi was 23 months versus 20 months with lenvatinib-sorafenib. The 24-month overall survival was 49% with ipi-nivo versus 39%. And the overall response rate with nivo-ipi was 36% compared to 13%. So again, significantly improved clinical activity.   And when we talk about immunotherapy combinations, the question that comes to mind is how well is this tolerated? There's a lot of work and iteration that took place in figuring out what the right combination strategy of ipi and nivo should be, because some of the earlier studies did demonstrate fairly high adverse events in this group of patients. So on this study, we saw that grade 3 or 4 treatment related adverse events were seen in 41% of people who received nivo-ipi and 42% if they received lenvatinib or sorafenib. So, certainly a high proportion of treatment related adverse events, but probably also reflective of the disease population, which is being tested, because those numbers were fairly similar in the control arm as well.  So we've known that nivo-ipi is active in HCC. There is an approval in the second-line space, so it remains to be seen if this data helps propel nivo-ipi to the first-line space so we end up with another combination regimen for patients with advanced hepatocellular carcinoma.  Geraldine Carroll: Excellent. Well, before we wrap up the podcast, I'd like to ask you about LBA3511. In this study, investigators looked at total neoadjuvant treatment with long course radiotherapy versus concurrent chemoradiotherapy in local advanced rectal cancer with high risk factors. So this was a multicenter, randomized, open label, phase 3 trial. What are your key takeaways here? Dr. Shaalan Beg: Key takeaway here is that total neoadjuvant therapy was better than the conventional chemoradiation followed by chemo. So this clinical trial enrolled people with T4a/b resectable disease with clinical N2 stage, and they were randomized, as you mentioned, to receiving chemoradiation with radiation capecitabine followed by surgery, and then CAPOX or capecitabine versus chemo, short-course radiation, and additional chemotherapy followed by surgery.  And when we compare both arms, the total neoadjuvant therapy led to improved disease-free survival, improved PCR rates compared to standard concurrent neoadjuvant chemo radiotherapy in this group of patients. The two arms were fairly well-balanced. The number of T4 lesions was a little higher in the chemoradiation group. There were 49% in the chemo radiation group versus 46% had clinically T4 disease, but the nodal status was fairly similar. We should keep in mind that the other baseline characteristics were fairly well balanced.  And when we look at the outcomes, the disease-free survival probability at 36 months was 76% in the total neoadjuvant group compared to 67% with chemoradiation. And the metastasis free survival in total neoadjuvant therapy was 81% versus 73%. So a fairly compelling difference between the two arms, which did translate into an overall survival of 89% versus 88% in the two groups. So definitely higher disease-free survival and metastasis free survival, no difference on the overall survival with these groups. And it talks about the importance of intensifying chemotherapy upfront in this group of patients who can have a fairly high burden of disease and may struggle with receiving chemotherapy postoperatively. Geraldine Carroll: Excellent. Well, thank you, Dr. Beg, for sharing your fantastic insights with us on these key studies from the 2024 ASCO Annual Meeting. It's certainly a very exciting time in GI oncology. Dr. Shaalan Beg: Absolutely. Thank you for bringing these studies out, because I think a lot of these are practice-changing and can start impacting the clinical care that we're giving our patients right now. Geraldine Carroll: Thank you to our listeners for joining us today. You'll find links to the abstracts discussed today in the transcript of this episode. Finally, if you value the insights that you hear on the podcast, please take a moment to rate, review, and subscribe wherever you get your podcasts.   Disclaimer: The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement.   Find out more about today's speakers: Dr. Shaalan Beg   @ShaalanBeg     Follow ASCO on social media:   @ASCO on Twitter  ASCO on Facebook  ASCO on LinkedIn    Disclosures:  Dr. Shaalan Beg:   Consulting or Advisory Role: Ispen, Cancer Commons, Foundation Medicine, Genmab/Seagen   Speakers' Bureau: Sirtex   Research Funding (An Immediate Family Member): ImmuneSensor Therapeutics   Research Funding (Institution): Bristol-Myers Squibb, Tolero Pharmaceuticals, Delfi Diagnostics, Merck, Merck Serono, AstraZeneca/MedImmune  

La fintech HERO (https://www.heropay.eu) annonce une levée de fonds de 11,3 millions d'euros, menée par le fonds d'investissement américain Valar Ventures et son investisseur historique SquareOne. Ce financement vise à répondre aux besoins de trésorerie des TPE-PME en Europe, leur offrant des solutions de financement compétitives pour faire face à leur croissance.Pour en parler nous recevons Roland Jais-Nielsen co fondateur et CEO de HERO:Become a supporter of this podcast: https://www.spreaker.com/podcast/frenchweb-business--3299227/support.

Treatment with perioperative chemotherapy, with chemotherapy before and after surgery, brought superior outcomes for patients with locally advanced esophageal adenocarcinoma, in research reported to the 2024 ASCO Annual Meeting. Lead author Jens Höppner FAChirg, FACS, MD, Director of the Department of Surgery in the University Medical Center at the University of Bielefeld in Germany, spoke with Oncology Times reporter Peter Goodwin about his group’s comparison of neoadjuvant therapy using the CROSS (41.4 Gy plus carboplatin/paclitaxel) regimen followed by surgery, with the use of an alternative protocol: perioperative FLOT (5-FU/ leucovorin/oxaliplatin/docetaxel) and surgery, in which chemotherapy is given both before and after curative surgery.

Some oncologists may have already started counting down to ASCO 2025. However, Michael and Josh are still digesting the interesting world of ASCO 2024, specifically upper GI and Hepatobiliary Cancers. Like the eponymous lead of the 1992 classic Aladdin, several diamonds lie in the rough.We cover perioperative FLOT in the metastatic setting, but most excitingly, it is a potentially new groundbreaking treatment for hepatocellular carcinoma.Links to studies discussed in this episode (subscription may be required)ECOG-ACRIN EA2174: https://meetings.asco.org/2024-asco-annual-meeting/15831?presentation=231157%23231157ROTG 0848: https://meetings.asco.org/2024-asco-annual-meeting/15831?presentation=231157%23231157CHECKMATE 9DW: https://meetings.asco.org/2024-asco-annual-meeting/15831?presentation=231157%23231157RENAISSANCE: https://meetings.asco.org/2024-asco-annual-meeting/15831?presentation=231157%23231157For more episodes, resources and blog posts, visit www.inquisitiveonc.comPlease find us on Twitter @InquisitiveOnc!If you want us to look at a specific trial or subject, email us at inquisitiveonc@gmail.comOncology for the Inquisitive Mind is recorded with the support of education grants from Pfizer, Gilead Pharmaceuticals and Merck Pharmaceuticals. Our partners have no editorial rights or early previews, and they have access to the episode at the same time you do.Art courtesy of Taryn SilverMusic courtesy of AlisiaBeats: https://pixabay.com/users/alisiabeats-39461785/Disclaimer: This podcast is for educational purposes only. If you are unwell, seek medical advice. Hosted on Acast. See acast.com/privacy for more information.

Case Discussion 114 Answer: FLOT chemotherapy regimen and cardiovascular system

Flot regnskab fra industrikonglomeratet Schouw & Co. i fredags, men aktien kan alligevel ikke helt følge med. Millionærklubben undersøger hvorfor med selskabets CEO Jens Bjerg Sørensen og aktieanalytiker Michael Friis Jørgensen i studiet. Sidst i udsendelsen også besøg af Mikael Bak fra Dansk Aktionærforening, der pt. spurter rundt til landets mange generalforsamlinger. Vært: Bodil Johanne Gantzel. See omnystudio.com/listener for privacy information.

¿Qué fue de la biblioteca de Hitler y qué valor tiene? Relacionados: Podcast AFR Nº 121: Secretos esotéricos del Nazismo https://alfilodelarealidad.com/podcast-afr-no-121-secretos-esotericos-del-nazismo/ ¿Hallazgo de un submarino nazi en Argentina? https://alfilodelarealidad.com/hallazgo-de-un-submarino-nazi-en-argentina/ Podcast AFR Nº 302: Parapsicología nazi y Sociedad Vril https://alfilodelarealidad.com/podcast-afr-no-302-parapsicologia-nazi-y-sociedad-vril/ El refugio Nazi en Argentina menos pensado https://alfilodelarealidad.com/refugionazienargentina/ Una reflexión sobre “OVNIs Nazis” https://alfilodelarealidad.com/una-reflexion-sobre-ovnis-nazis/ Y mucho más: https://alfilodelarealidad.com/?s=nazismo Plataforma de cursos (https://miscursosvirtuales.net). "FORMACIONES DE GUÍAS DE TEMAZCAL" para notificar fechas, lugares, Niveles Avanzados, Retiros de formación complementarios, detalles, etc., de las próximas Formaciones que en ese sentido haremos desde "Casa del Cóndor". Interesados: súmense al grupo donde concentraremos las actualizaciones: https://www.facebook.com/groups/153766088413706 * * * Programa de Afiliados * * * iVoox comparte con AFR un pequeño porcentaje si usas uno de estos enlaces: * Disfruta de la experiencia iVoox sin publicidad, con toda la potencia de volumen, sincronización de dispositivos y listas inteligentes ilimitadas: Premium anual https://www.ivoox.vip/premium?affiliate-code=68e3ae6b7ef213805d8afeeea434a491 Premium mensual https://www.ivoox.vip/premium?affiliate-code=7b7cf4c4707a5032e0c9cd0040e23919 * La mejor selección de podcasts en exclusiva con iVoox Plus Más de 50.000 episodios exclusivos y nuevos contenidos cada día. ¡Suscríbete y apoya a tus podcasters favoritos! Plus https://www.ivoox.vip/plus?affiliate-code=258b8436556f5fabae31df4e91558f48 Más sobre el mundo del Misterio en alfilodelarealidad.com

Composer and Latin Grammy-nominated conductor Dimitri Cervo presents in this album his complete piano works, in a comprehensive selection of pieces that span nearly four decades of creative output.   Interpreted by Lucas Thomazinho, one of the most prominent figures in the contemporary piano scene, the album showcases the ongoing artistic evolution and rich diversity of musical influences that permeate Cervo's body of work.   The album features three distinct phases in Cervo's compositional journey: The first phase, spanning from 1985 to 1997, is notably marked by the influence of classical piano repertoire, with special reverence for the works of Scriabin and Chopin, whose works were intensely studied by Cervo during his academic piano training. Standouts from this phase include Estudo (1985), with its intricate rhythmic changes, and Prelúdio Titanic (1985), an evocative piece that portrays the history of the famous ship. The second creative phase (1998-2010) is characterized by the innovative fusion of distinctive elements of Brazilian music with minimalism. Finally, the third and current phase, which began in 2011 and continues to the present day, is marked by the amalgamation of various influences and the consolidation of the composer's artistic maturity and innovative vision in the contemporary musical landscape. Tracks1. Estudo (1985) (01:11) 2. Prelúdio in B Major (1985) (01:49) 3. Prelúdio “Titanic” (1985) (01:39) 4. Prelúdio in C-Sharp (1988) (01:27) 5. Toccata Fantástica (1989) (04:41) 6. Prelúdio I (1990) (01:57) 7. Prelúdio II (1991) (02:33) 8. Prelúdio III (1990) (02:48) 9. Prelúdio IV (1995) (03:33) 10. Flot (1994) (07:28) 11. Brasil 2000 (1998) (07:54) 12. Tema para Filme I (2005) (03:22) 13. Tema para Filme II (1989) (03:00) 14. Tema para Filme III (2007) (04:02) 15. Tema para Filme IV (2008) (01:35) 16. Tema para Filme V (2008) (04:32) 17. Tema para Filme VI (1987) (00:59) 18. Tema para Filme VII (2021) (01:23) 19. Variações Ternas Sobre um Tema de Ronaldo Miranda (2022) (05:41) Classical Music Discoveries is sponsored by Uber. @CMDHedgecock#ClassicalMusicDiscoveries #KeepClassicalMusicAlive#CMDGrandOperaCompanyofVenice #CMDParisPhilharmonicinOrléans#CMDGermanOperaCompanyofBerlin#CMDGrandOperaCompanyofBarcelonaSpain#ClassicalMusicLivesOn#Uber#AppleClassical Please consider supporting our show, thank you!Donate (classicalmusicdiscoveries.store) staff@classicalmusicdiscoveries.comThis album is broadcast with the permission of Bárbara Leu from Azul Music.         

Husk navnet, Sofia Thøgersen. Danmarks "nye" løbedronning. Den blot 18-årige danske løber har haft en fantastisk sæson og er nok den danske løber med det højeste internationale niveau lige nu. Vi har taget en snak med hende, efter hun blev en flot nummer 2 ved Europamesterskabet i Cross i U20-klassen i Belgien, hvilket kroner en flot sæson, som har budt på flere nordiske mesterskaber, danske senior mesterskaber, hele tre medaljer ved EM og ikke mindst en seniorrekord på den klassiske 1500 meter distance ved VM. Hvor hun med tiden 4.05 løb den næsthurtigste tid nogensinde af en europæisk pige under 20 år. Hør om følgende: - De taktiske overvejelser omkring løbet - Hvordan hun med vilje valgte at løbe lidt længere for at undgå alt for meget mudder - Sparringen med nogle af de bedste unge atleter i verden - Hendes træning - Den massive succesoplevelse ved verdensmesterskabet - Hvordan hun passer skolen, imens hun tager verden rundt på træningslejr - Den mærkelige følelse, da hendes træningskammeret duellerede med hendes landsmand. Hvem skulle hun holde med? - Hvordan man fejrer en sølvmedalje? - 2024-sæsonen som forhåbenligt byder på EM og OL. Gæst: Sofia Thøgersen Vært: Henrik Them Frontrunner er produceret af Team Thempo

Hej, w tym odcinku serii Powojnie wracam do lat 90-tych i sporu Rosji z Ukrainą. Jednym z elementów politycznej wojny na Wschodzie była kwestia Krymu. Współpracujący z Moskwą krymscy komuniści opowiadali się za integracją z państwem rosyjskim. Jednak zabiegi nowego prezydenta Ukrainy i opieszałość Kremla powstrzymało ten proces. W pewnym momencie na półwyspie powstała nawet niezależna samozwańcza republika (skąd my to znamy). Drugą kością niezgody między Kijowem a Moskwą była sprawa Floty Czarnomorskiej. Okręty do niej należące miały stanowić podstawę dla budowanej ukraińskiej marynarki wojennej. Na to jednak nie chciał zgodzić się prezydent Rosji Borys Jelcyn. Część historyków uważa, że był to czas gdy oba kraje znalazły się w stanie "zimnej wojny", która mogła zakończyć się realnym konfliktem. Więcej na ten temat w najnowszym odcinku serii Powojnie.

Investis dans les startups les plus inaccessibles du marché avec Blast.Club

durée : 00:03:39 - Le Pourquoi du comment : histoire - par : Gérard Noiriel - En 1881, la loi sur la liberté de la presse est votée et Émile Zola renonce au journalisme. Il a été l'un des premiers à comprendre le rôle essentiel que jouent les médias au sein des régimes démocratiques en mobilisant les émotions des lecteurs pour créer des "secousses incessantes" dans le pays.

Value developing a FLOT line in your soul as your number one priority. Using God's 10 problem-solving devices is exactly how to live the Christian way of life. “Do not be conformed to this world but be transformed by the renewing of your mind so that you may prove what the will of God is, that which is good and acceptable and perfect” (Rom 12:2). God left you here for a reason and that is to grow to spiritual maturity, fulfill your spiritual gift and glorify God to the maximum. Personal love for God is your motivation to do this. If you don't understand the essence of God, you can't love God. Happiness is a system of thought in your soul based on God's Word. “Happy are those who hear My word and keep it” (Luke 11:28). Occupation with Christ is having the thinking of our Lord. God makes a direct demand on your volition to be occupied with Christ which is a mandate to be consistent in the metabolization of God's Word in your soul. “Fixing our eyes on Jesus, the author and perfecter of our faith” (Heb 12:2). Click for Full Transcript: https://rhem.pub/value-flot-4da9c4

The strength of your spiritual life depends on using God's 10 problem-solving devices as the FLOT line in your soul. If you don't understand Rebound (1 John 1:9) and the Filling of the Holy Spirit, you are not living the Christian life. Religious rituals are meaningless unless you are filled with the Holy Spirit. “For we walk by faith, not by sight” (2 Cor 5:7). Faith is trust in God's provisions. Learning to walk by faith pleases God. “It is good for me that I was afflicted that I may learn Your statutes” (Ps 119:71). If you want to grow up spiritually you must learn God's Word. Grace Orientation will keep you stable in times of hardship and suffering. The power of Christ in His grace provisions. “My grace is sufficient for you, for power is perfected in weakness” (2 Cor 12:9-10).  Click for Full Transcript: https://rhem.pub/value-flot-98322f

❓Jak ważna dla Rzeszy Niemieckiej była jej flota handlowa? ❓Dlaczego decyzje Adolfa Hitlera omal nie doprowadziły do zagłady niemieckiej floty handlowej? ❓Dlaczego wybuch wojny zaskoczył niemieckie statki na morzach i oceanach? ⚠️ O tym i o wielu innych kwestiach związanych niemiecką flotą handlową opowiemy Wam w tym odcinku - posłuchajcie⚠️ Jeżeli podoba Ci się odcinek możesz nas wesprzeć w serwisie Patronite.pl:

Occupation with Christ is the greatest treasure a Christian can possess. It comes gradually through learning and applying God's Word in your life. The knowledge of God fuels your faith and the development of a FLOT line in your soul so you can represent Jesus Christ to others. “But we have this treasure in our earthly bodies so that the surpassing greatness of the power will be of God and not from ourselves” (2 Cor 4:7). Every treasure God provides is given through Christ beginning with the free gift of eternal life. Your spiritual life depends on encouragement in Christ Jesus that comes from knowing the Word of God. “Sanctify the Lord Jesus Christ in your hearts” (1 Pet 3:15). Click for Full Transcript: https://rhem.pub/gods-treasure-4abf4a